# Zymeworks Inc.: overview ZYME · Nasdaq · CIK 1937653 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/zyme.md) · [Financials](/companies/zyme/financials.md) · [Filings](/companies/zyme/filings.md) · [Insiders](/companies/zyme/insiders.md) Latest reported revenue: [$4.6m](/filings/0001937653-26-000047.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001937653-26-000047). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [16.0](/filings/0001937653-25-000077.md) | [31.0 d](/filings/0001937653-26-000015.md) | [27.1](/filings/0001937653-26-000034.md) | [48.7](/filings/0001937653-26-000047.md) | [27.6](/filings/0001937653-25-000077.md) | [2.5 d](/filings/0001937653-26-000015.md) | [2.4](/filings/0001937653-26-000034.md) | [4.6](/filings/0001937653-26-000047.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(213.8%)](/filings/0001937653-25-000077.md) | [(71.6%) d](/filings/0001937653-26-000015.md) | [(94.5%)](/filings/0001937653-26-000034.md) | [(1.4%)](/filings/0001937653-26-000047.md) | [(80.1%)](/filings/0001937653-25-000077.md) | [(1755.5%) d](/filings/0001937653-26-000015.md) | [(1956.7%)](/filings/0001937653-26-000034.md) | [(919.0%)](/filings/0001937653-26-000047.md) | | Net margin | % | [(186.6%)](/filings/0001937653-25-000077.md) | [(75.8%) d](/filings/0001937653-26-000015.md) | [(83.5%)](/filings/0001937653-26-000047.md) | [4.8%](/filings/0001937653-26-000047.md) | [(71.0%)](/filings/0001937653-25-000077.md) | [(1638.5%) d](/filings/0001937653-26-000015.md) | [(1834.0%)](/filings/0001937653-26-000047.md) | [(980.8%)](/filings/0001937653-26-000047.md) | | Diluted EPS | $ per share | [(0.39)](/filings/0001937653-25-000077.md) | not reported | [(0.30)](/filings/0001937653-26-000034.md) | [0.03](/filings/0001937653-26-000047.md) | [(0.26)](/filings/0001937653-25-000077.md) | not reported | [(0.59)](/filings/0001937653-26-000034.md) | [(0.62)](/filings/0001937653-26-000047.md) | | Free cash flow | $m | [(6.8) d](/filings/0001937653-25-000077.md) | [(41.8) d](/filings/0001937653-26-000015.md) | [(3.4)](/filings/0001937653-26-000034.md) | [11.6 d](/filings/0001937653-26-000047.md) | [(31.8) d](/filings/0001937653-25-000077.md) | [(10.8) d](/filings/0001937653-26-000015.md) | [(45.9)](/filings/0001937653-26-000034.md) | [(31.9) d](/filings/0001937653-26-000047.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [26.7](/filings/0001937653-24-000019.md) | [412](/filings/0001937653-25-000014.md) | [76.0](/filings/0001937653-26-000015.md) | [76.3](/filings/0001937653-26-000015.md) | [106](/filings/0001937653-26-000015.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(808.2%)](/filings/0001937653-24-000019.md) | [31.6%](/filings/0001937653-25-000014.md) | [(181.6%)](/filings/0001937653-26-000015.md) | [(179.7%)](/filings/0001937653-26-000015.md) | [(87.3%)](/filings/0001937653-26-000015.md) | | Net margin | % | [(794.0%)](/filings/0001937653-24-000019.md) | [30.1%](/filings/0001937653-25-000014.md) | [(156.1%)](/filings/0001937653-26-000015.md) | [(160.8%)](/filings/0001937653-26-000015.md) | [(76.6%)](/filings/0001937653-26-000015.md) | | Diluted EPS | $ per share | [(4.61)](/filings/0001937653-24-000019.md) | [1.90](/filings/0001937653-25-000014.md) | [(1.72)](/filings/0001937653-26-000015.md) | [(1.62)](/filings/0001937653-26-000015.md) | [(1.08)](/filings/0001937653-26-000015.md) | | Free cash flow | $m | [(205)](/filings/0001937653-24-000019.md) | [136](/filings/0001937653-25-000014.md) | [(121)](/filings/0001937653-26-000015.md) | [(112)](/filings/0001937653-26-000015.md) | [(34.5)](/filings/0001937653-26-000015.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/zyme/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [EcoR1 Capital, LLC](/funds/1587114.md) | 2026-06-30 | $600.4m | 22,970,388 | | Unchanged | | [Rubric Capital Management LP](/funds/1687509.md) | 2026-06-30 | $183.0m | 7,000,000 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $111.1m | 4,251,030 | | Reduced −302,858 | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $109.3m | 4,182,953 | | Added +672,875 | | [BVF INC/IL](/funds/1056807.md) | 2026-06-30 | $95.4m | 3,649,142 | | Reduced −85,000 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $58.3m | 2,231,260 | | Reduced −249,308 | | [BNP PARIBAS ASSET MANAGEMENT Holding S.A.](/funds/1520354.md) | 2026-06-30 | $46.6m | 1,781,116 | | Reduced −126,923 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $40.8m | 1,558,998 | | Reduced −146,582 | | [Assenagon Asset Management S.A.](/funds/1546007.md) | 2026-06-30 | $32.7m | 1,252,027 | | Added +524,041 | | [Assenagon Asset Management S.A.](/funds/1546007.md) | 2026-06-30 | $32.7m | 1,252,027 | | Added +524,041 | ## Recent filings [All 330 filings](/companies/zyme/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-26 | 16:11 ET | [DEF 14A](/filings/0001193125-26-431936.md) | Proxy statement, period 2026-12-15 | 0001193125-26-431936 | | 2026-10-23 | 06:07 ET | [8-K](/filings/0001937653-26-000055.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001937653-26-000055 | | 2026-09-23 | 16:06 ET | [8-K](/filings/0001193125-26-399383.md) | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 2.03 New direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-399383 | | 2026-08-25 | 10:54 ET | [8-K](/filings/0001937653-26-000051.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001937653-26-000051 | | 2026-08-06 | 16:11 ET | [10-Q](/filings/0001937653-26-000047.md) | Quarterly report, period 2026-06-30 | 0001937653-26-000047 | | 2026-08-06 | 16:09 ET | [8-K](/filings/0001937653-26-000046.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001937653-26-000046 | | 2026-06-29 | 07:20 ET | [8-K](/filings/0001193125-26-286829.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-286829 | | 2026-05-14 | 16:29 ET | [8-K](/filings/0001193125-26-224161.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-224161 | | 2026-05-07 | 16:15 ET | [10-Q](/filings/0001937653-26-000034.md) | Quarterly report, period 2026-03-31 | 0001937653-26-000034 | | 2026-05-07 | 16:10 ET | [8-K](/filings/0001937653-26-000033.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001937653-26-000033 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001937653-26-000015.md), filed Mar 2, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/021cc864-d142-47a6-b5c5-44eccbe1ce41) ## About the filer - CIK: 1937653 - Tickers: ZYME - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 16:15 ET. No prices; not investment advice.